시장보고서
상품코드
1090133

세계의 헌팅턴병 치료 시장 규모 : 치료법별(증상 치료, 질병 조절 요법), 지역별 예측(2022-2028년)

Global Huntington´s Disease Treatment Market Size study, by Treatment (Symptomatic treatment, Disease-modifying therapies) and Regional Forecasts 2022-2028

발행일: | 리서치사: Bizwit Research & Consulting LLP | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 헌팅턴병 치료 시장 규모는 2021년에 약 3억 6,200만 달러로 평가되었고, 2022-2028년간 19.6% 이상의 성장률로 성장할 것으로 예상됩니다.

시장 성장을 뒷받침하는 주요인으로는 유럽 및 미국 국가에서 헌팅턴병의 높은 유병률, 질병 조절 요법의 충실한 제품 파이프라인 등을 들 수 있습니다. 한편, 높은 의약품 개발 비용이 시장 성장을 방해할 전망입니다.

세계의 헌팅턴병(Huntington's Disease) 치료 시장을 조사했으며, 시장 개요, 시장 분석, 치료법·지역별 분석 및 경쟁 구도 등의 정보를 제공합니다.

목차

제1장 개요

제2장 세계의 헌팅턴병 치료 시장 정의와 범위

제3장 세계의 헌팅턴병 치료 시장 역학

  • 헌팅턴병 치료 시장 영향 분석(2020-2028년)

제4장 세계의 헌팅턴병 치료 시장 업계 분석

  • Porter's Five Forces 모델
  • PEST 분석
  • 투자 채용 모델
  • 애널리스트의 추천 사항과 결론
  • 주요 투자 기회
  • 주요 성공 전략

제5장 리스크 평가 : COVID-19의 영향

    • 업계에 대한 COVID-19의 전체적인 영향 평가
    • COVID-19 이전 및 COVID-19 이후의 시장 시나리오

제6장 세계의 헌팅턴병 치료 시장 : 치료법별

  • 시장 현황
  • 치료법별 세계의 헌팅턴병 치료 시장 실적-잠재성 분석
  • 치료법별 세계의 헌팅턴병 치료 시장 추정과 예측(2018-2028년)
  • 헌팅턴병 치료 시장, 하위 부문 분석
    • 증상 치료
    • 질병 조절 요법

제7장 세계의 헌팅턴병 치료 시장 : 지역별

  • 지역 시장 현황
  • 북미
    • 미국
    • 캐나다
  • 유럽 현황
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양 현황
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카 현황
    • 브라질
    • 멕시코
  • 기타 지역

제8장 경쟁 정보

  • 주요 시장 전략
  • 기업 개요
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Hetero
    • Lupin
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Valeant Pharmaceuticals International Inc
    • Alnylam Pharmaceuticals Inc.

제9장 조사 프로세스

LSH 22.07.07

Global Huntington's Disease Treatment Market is valued approximately USD 362.0 million in 2021 and is anticipated to grow with a healthy growth rate of more than 19.6 % over the forecast period 2022-2028. CAG expansions in the Huntingtin (Htt) gene cause Huntington's Disease (HD), a degenerative neurological disorder. As per the Center of Disease Control In the United States, it affects one in every 10,000 persons. CAG expansions in HD patients range from 36 to 200, compared to less than 35 in healthy people. The prevalence varies by a factor of 10 between geographic places, which can be attributed to differences in case detection and diagnostic criteria. Asia has always had a lower incidence than Europe, North America, and Australia. The use of immunomodulatory medicines to target the hyperactive immune system in HD is the focus of several small molecules under clinical development. The market is likely to be driven by Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments. As per CDC, In North America, HD affects about 30,000 persons, with an incidence of 5.7 per 100,000. Children with HD are far less common, accounting for just approximately 5% to 10% of all cases. It affects up to ten persons out of every 100,000 in Europe. Institutes and universities are working on research programmes to discover novel therapeutics for the condition, such as cell and gene-based therapies. Huntington's disease treatment will most likely focus on reversing cell loss due to degeneration. Neurogenesis and neuron regeneration are two new therapies that use stem cell therapy to restore or manipulate neuron cells. Another strategy is to reduce the creation of Huntingtin protein, which is the primary cause of Huntington's disease. However, over the projection period of 2022-2028, the market's growth would be hampered by the high cost of drug development.

The key regions considered for the Global Huntington's Disease Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. The Huntington's disease treatment market in North America had the biggest revenue share. This increase is attributable to the disease's high burden, rising healthcare costs, technology improvements, proactive government actions, and improved patient awareness of Huntington's disease treatment options. H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., for example, are supporting market expansion by introducing symptom control medicines. Due to increased product penetration, untapped potential, and the growing prevalence of the condition in emerging nations, the market for Huntington's disease therapy in Asia Pacific is predicted to rise at a substantial CAGR over the forecast period. The market in the region is predicted to increase as a result of an increasing number of government initiatives aimed at improving the population's health.

Major market player included in this report are:

H. Lundbeck A/S

Teva Pharmaceutical Industries Ltd.

Bausch Health Companies Inc.

Hetero

Lupin

Hikma Pharmaceuticals PLC

Dr. Reddy's Laboratories Ltd.

Sun Pharmaceutical Industries Ltd.

Valeant Pharmaceuticals International Inc

Alnylam Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment

Symptomatic treatment

Disease-modifying therapies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Huntington's Disease Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Huntington's Disease Treatment Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Huntington's Disease Treatment Market, by Treatment, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Huntington's Disease Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Huntington's Disease Treatment Market Dynamics

  • 3.1. Huntington's Disease Treatment Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increased adoption of novel therapeutics
      • 3.1.1.2. Rise in target population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost associated with Drug Development
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in R&D activities
      • 3.1.3.2. Favourable government initiatives

Chapter 4. Global Huntington's Disease Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 market scenario

Chapter 6. Global Huntington's Disease Treatment Market, by Treatment

  • 6.1. Market Snapshot
  • 6.2. Global Huntington's Disease Treatment Market by Treatment, Performance - Potential Analysis
  • 6.3. Global Huntington's Disease Treatment Market Estimates & Forecasts by Treatment 2018-2028 (USD Million)
  • 6.4. Huntington's Disease Treatment Market, Sub Segment Analysis
    • 6.4.1. Symptomatic treatment
    • 6.4.2. Disease-modifying therapies

Chapter 7. Global Huntington's Disease Treatment Market, Regional Analysis

  • 7.1. Huntington's Disease Treatment Market, Regional Market Snapshot
  • 7.2. North America Huntington's Disease Treatment Market
    • 7.2.1. U.S. Huntington's Disease Treatment Market
      • 7.2.1.1. Treatment breakdown estimates & forecasts, 2018-2028
    • 7.2.2. Canada Huntington's Disease Treatment Market
  • 7.3. Europe Huntington's Disease Treatment Market Snapshot
    • 7.3.1. U.K. Huntington's Disease Treatment Market
    • 7.3.2. Germany Huntington's Disease Treatment Market
    • 7.3.3. France Huntington's Disease Treatment Market
    • 7.3.4. Spain Huntington's Disease Treatment Market
    • 7.3.5. Italy Huntington's Disease Treatment Market
    • 7.3.6. Rest of Europe Huntington's Disease Treatment Market
  • 7.4. Asia-Pacific Huntington's Disease Treatment Market Snapshot
    • 7.4.1. China Huntington's Disease Treatment Market
    • 7.4.2. India Huntington's Disease Treatment Market
    • 7.4.3. Japan Huntington's Disease Treatment Market
    • 7.4.4. Australia Huntington's Disease Treatment Market
    • 7.4.5. South Korea Huntington's Disease Treatment Market
    • 7.4.6. Rest of Asia Pacific Huntington's Disease Treatment Market
  • 7.5. Latin America Huntington's Disease Treatment Market Snapshot
    • 7.5.1. Brazil Huntington's Disease Treatment Market
    • 7.5.2. Mexico Huntington's Disease Treatment Market
  • 7.6. Rest of The World Huntington's Disease Treatment Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. H. Lundbeck A/S
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Teva Pharmaceutical Industries Ltd.
    • 8.2.3. Bausch Health Companies Inc.
    • 8.2.4. Hetero
    • 8.2.5. Lupin
    • 8.2.6. Hikma Pharmaceuticals PLC
    • 8.2.7. Dr. Reddy's Laboratories Ltd.
    • 8.2.8. Sun Pharmaceutical Industries Ltd.
    • 8.2.9. Valeant Pharmaceuticals International Inc
    • 8.2.10. Alnylam Pharmaceuticals Inc.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제